Company / R&D per Share
LEXICON PHARMACEUTICALS, INC. R&D per Share History
FY2013-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.16
FY2025
5-year range
$0.16 / $1.58
FY2021-FY2025
Trend
-49.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share has declined for 4 consecutive years, from $1.58 in FY2018 to $0.16 in FY2025.
Based on SEC 10-K filings.
0.16 in FY2025 with a 10-year CAGR of -18.3%.
Declined from $0.38 to $0.16 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -18.3%
Key checks
Key Insights
- LEXICON PHARMACEUTICALS, INC.'s r&d per share has declined for 4 consecutive years.
- In FY2025, r&d per share decreased 49.1% year-over-year.
- Peak r&d per share was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -1.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.16 | -49.1% |
| FY2024 | $0.32 | -15.7% |
| FY2023 | $0.38 | -74.0% |
| FY2019 | $1.45 | -7.9% |
| FY2018 | $1.58 | +71.8% |
| FY2017 | $0.92 | -21.4% |
| FY2016 | $1.17 | -4.4% |
| FY2015 | $1.22 | +625.6% |
| FY2014 | $0.17 | -37.4% |
| FY2013 | $0.27 | +3.9% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026